Ine Nulmans

Ms. Ine Nulmans


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
INIne Nulmans
Ine Nulmans
SLSien Lequeue
Sien Lequeue
LDLiesbeth Desmet
Liesbeth Desmet
JNJessie Neuckermans
Jessie Neuckermans
JKJoery De Kock
Joery De Kock
Background: Phenylketonuria (PKU) is an inborn error of amino acid metabolism caused by a deficiency of the L-phenylalanine-4-hydroxylase enzyme or its cofactor tetrahydrobiopterin (BH4) resulting in increased levels of phenylalanine (Phe) in blood and cerebrospinal fluid. Symptoms include hypopigmentation, a musty, mouse-like smell and various neurological complications. Main text: Treatment options include (i) dietary restriction of Phe with supplementation of other amino acids and micronutrients through medical mixtures, (ii) daily dosing of large neutral amino acids, (iii) synthetic forms of BH4 and (iv) bacterial phenylalanine ammonia lyase enzymes. The primary goal of treatment is to lower blood Phe levels and improve quality of life. However, treatment is very demanding for patients as well as their families, and not all treatment options are applicable to every patient. Conclusion: This review gives a state-of-the-art overview of current treatment options for all PKU patients and additionally speculates on future therapeutic approaches.

4 August 2022 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
GDGigly Gwenny Del'haye
Gigly Gwenny Del'haye
INIne Nulmans
Ine Nulmans
SBSandrine P. Bouteille
Sandrine P. Bouteille
KSKarolien Sermon
Karolien Sermon
BWBrecht Wellekens
Brecht Wellekens
Joery De KockJoery De Kock
Joery De Kock
Adverse outcome pathways (AOPs), introduced in modern toxicology, intend to provide an evidence-based representation of toxicological effects and facilitate safety assessment of chemicals not solely based on laboratory animal in vivo experiments. However, some toxicological processes are too complicated to represent in one AOP. Therefore, AOP networks are developed that help understanding and predicting toxicological processes where complex exposure scenarios interact and lead to the emergence of the adverse outcome. In this study, we present an AOP network for breast cancer, developed after an in-depth survey of relevant scientific literature. Several molecular initiating events (MIE) were identified and various key events that link the MIEs with breast cancer were described. The AOP was developed according to Organization of Economic Co-Operation and Development (OECD) guidance, weight of evidence was assessed through the Bradford Hill criteria and confidence was tested by the OECD key questions. The AOP network provides a straightforward understanding of the disease onset and progression at different biological levels. It can be used to pinpoint knowledge gaps, identify novel therapeutic targets and act as a stepping stone for the development of novel in vitro test methods for hazard identification and risk assessment of newly developed chemicals and drugs.

4 September 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
INIne Nulmans
Ine Nulmans
SLSien Lequeue
Sien Lequeue
LDLiesbeth Desmet
Liesbeth Desmet
GDGigly G. Del’HAye
Gigly G. Del’HAye
NSNina S. Salvi
Nina S. Salvi
Joery De KockJoery De Kock
Joery De Kock
Phenylketonuria (PKU), an autosomal recessive disease caused by a deficiency in the phenylalanine-4-hydroxylase enzyme or its cofactor tetrahydrobiopterin, is characterized by excessive phenylalanine (Phe) and reduced tyrosine (Tyr) levels and typically manifests neurologically. Even early treated PKU patients with proper metabolic control, obtained immediately after birth upon diagnosis of the disease, show late-onset neurological complications. Although the disease has already been researched for over 90 years, the complexity of its neurological pathophysiology has only recently been unraveled. Where it was initially thought that the neurological phenotype could be attributed to the increased Phe and decreased Tyr levels resulting in impaired neurotransmitter synthesis, it is now hypothesized that other processes including alterations in protein synthesis, oxidative stress, changes in bioenergetics and white matter disturbances play an important role in the development of these neurological manifestations. In this review, we aim to guide you through the complex maze of the brain pathophysiology observed in PKU while providing a new perspective on future treatment strategies in order to completely overcome symptom onset.

8 August 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SLSien Lequeue
Sien Lequeue
HAHind Allach
Hind Allach
INIne Nulmans
Ine Nulmans
LDLiesbeth Desmet
Liesbeth Desmet
NSNina Stefanie Salvi
Nina Stefanie Salvi
Joery De KockJoery De Kock
Joery De Kock

27 September 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
INIne Nulmans
Ine Nulmans
CLCamille Annie Laga
Camille Annie Laga
NSNina Stefanie Salvi
Nina Stefanie Salvi
LDLiesbeth Desmet
Liesbeth Desmet
SLSien Lequeue
Sien Lequeue
JKJoery De Kock
Joery De Kock
Inborn errors of tyrosine metabolism result in patient’s inability to degrade tyrosine. Current treatment consists of a phenylalanine and tyrosine restricted diet and nitisinone, causing a block in the tyrosine degradation pathway. However, tyrosine levels will increase, leading to acquired hypertyrosinemia, implying the need for an add-on treatment. Tyrosine ammonia lyases (TAL) can provide such an add-on treatment as they catalyze the deamination of tyrosine into p-coumaric acid and ammonia. In this study, we developed a robust high-throughput screening (HTS) assay to assess the capacity of bacterial TAL enzymes to decrease excessive tyrosine. The assay is based on the spectrophotometric quantification of p-coumaric acid after conversion of tyrosine by bacterial TAL. As a benchmark, TAL from Flavobacterium johnsoniae (FjTAL) was used to optimize the assay. Optimal growth conditions for high-level protein expression were determined by incubating transformed Escherichia coli BL21 (DE3) cells at different temperatures during various incubation times. Subsequently, assay temperature and pH were optimized followed by testing different ratios of tyrosine assay mixes to bacterial lysate. Finally, assay robustness and functionality were evaluated. Optimal FjTAL expression was obtained after incubation for 24 h at 22 °C. Ideal assay conditions consist of a 80/20 ratio of 1 mM tyrosine assay mix to FjTAL lysate performed at pH 9.2 and 37 °C. The robustness test showed Z′ values > 0.4 and signal window values > 2 without edge or drift effects. As proof-of-principle, we successfully determined the catalytic activity of two other bacterial TAL enzymes RsTAL (5.718.10–3 ± 0.21.10–3) and SeSAM8 (4.658.10–3 ± 0.37.10–3). A robust, simple and reliable HTS assay was thus developed to evaluate the tyrosine degradation capacity of bacterial TAL enzymes.